- Vetter has confirmed plans to build a new injectable drug production facility in Saarland, Germany, with €480 million allocated to the first construction phase.
- Construction is scheduled to begin in Q2 2026, with operations expected to commence in 2031.
Vetter has confirmed plans to construct a new state-of-the-art production facility for injectable drugs in the Saarland region of southwest Germany. The project forms part of the company’s long-term global growth strategy, with construction scheduled to begin in the second quarter of 2026 and commercial operations expected to start in 2031.
The CDMO acquired an approximately 95-acre industrial site in Saarlouis at the end of 2024. Vetter has allocated around €480 million for the first phase of construction and expects the site to create up to 2,000 jobs in the long term. The European Commission has approved up to €47 million in state aid to support the project.
“With the construction of our new production facility in Germany, we continue on our path to sustainable growth. The investment strengthens the company’s commitment to Germany while supporting its role as a partner to the global pharmaceutical market.”
Udo J. Vetter, Chairman of the Advisory Board and member of the owner family
Alongside the Saarland project, Vetter has also begun construction of a new clinical production site in Des Plaines, Illinois, focused on aseptic manufacturing for early-stage clinical development. The company said this investment reflects continued demand for high-quality injectable drug services.
Vetter has been active in sterile pharmaceutical manufacturing for more than 75 years and continues to invest in its existing sites in Germany, Austria, and the United States. The planned Saarland facility is expected to significantly expand the company’s commercial production capacity and support future CDMO and contract manufacturing demand.
